Medicine
Angeliq 0.25 mg/0.5 mg tablet
Angeliq 0.25 mg/0.5 mg tablet is a prescription medicine containing Drospirenone and Estradiol for oral use, marketed by Bayer HealthCare Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25° C (68° to 77° F), excursions permitted to 15°–30° C…
Key facts
- Active ingredient (INN)
- Drospirenone and Estradiol
- Brand
- Angeliq
- Strength
- 0.25 mg/0.5 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 3 blister pack, 1 blister pack
- Marketing authorisation holder
- Bayer HealthCare Pharmaceuticals
- Manufacturer
- Bayer HealthCare Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25° C (68° to 77° F), excursions permitted to 15°–30° C (59°–86° F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 29 February 2012
- Identifiers
- RxCUI 1483549, 1483550, 1483551 +3DailyMed set ID 761834c2-6b61-4583-84c2-f1ca4a97c4f2NDC 50419-482Application NDA021355
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 3 blister pack in 1 carton / 28 tablet, film coated in 1 blister pack | 50419-482-03 | Bayer HealthCare Pharmaceuticals | 29 February 2012 |
| 1 blister pack in 1 carton / 14 tablet, film coated in 1 blister pack | 50419-482-72 | Bayer HealthCare Pharmaceuticals | 29 February 2012 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 28 September 2005 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Drospirenone and Estradiol
Clinical summary
Drospirenone and Estradiol is a fixed-dose combination of an estrogen and a progestin indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause. MedsAcross supplies Drospirenone and Estradiol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Drospirenone and EstradiolFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Angeliq prescribing information (Bayer HealthCare Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Angeliq 0.25 mg/0.5 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.